CPHI Japan 2026
Visit us to learn how Dr. Reddy’s can be your strategic partner across markets.
- 21-23 April 2026
- East Halls 1, 2 & 3, Tokyo Big Sight, Tokyo, Japan
Our Team at CPHI Japan 2026
Nirav Shah
Vice President, and Head, API - North Asia
Deepak Sapra
CEO, Pharmaceutical Services and Active Ingredients
About Dr.Reddy's API Business
We specialise in manufacturing and supplying a wide range of APIs for generic formulation manufacturers in India and overseas. The company has a diversified portfolio of 250+ active pharmaceutical ingredients, which are used in major therapeutic areas such as gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Our API manufacturing facilities adhere to cGMP (ICH Q7) and are inspected on a regular basis by international regulatory bodies. We have eight commercially inspected USFDA production plants, six in India and one each in Mexico and the United Kingdom.
Dr. Reddy’s API business operates in a number of global markets, including the United States of America, Latin America, Europe, India, Russia, and other CIS nations.
250+ APIs
8 Manufacturing sites
2000+ drug master files across global markets.
Over 325 ANDAs
filed 1100+ patents globally
Experience with complex APIs and formulations supporting early market entries
Preferred pharma API supplier for pharma companies in more than 80 countries
Sustainability is deeply embedded in our purpose and forms the core of our organization.
Our journey began with APIs in 1984, and we evolved from small molecules to large molecules and from APIs to finished formulations over the decades. Amidst this evolution, what has remained constant at the heart of our organization is a deep commitment to patients and the customers we serve through our core principles of collaboration and sustainability. By the end of FY2025, we had served over 756 million patients and continue our endeavours to reach over 1.5 billion patients globally by 2030. This means almost one in every five people on this planet will use Dr. Reddy’s product or service. The health of people is strongly linked to the health of our planet. That's why our integrated report also shows how sustainability and business are strongly linked.
Our ESG (Environment, Social & Governance) Goal:
Building the future responsibly
Our ESG goals are deeply embedded in our business strategy, guiding our efforts to create a significant and lasting positive impact on the planet and its people. We have made fair progress across several of these goals, even as a few continue to present challenges. We are committed to advancing our ESG journey, ensuring that as we prosper, we do so responsibly and with resilience.
What we achieved in the past year:
3.8
Bn total revenue (17% growth)
165
New products launched
111
DMFs filed, (1,630+ Cumulative DMFs)
249
Dossiers, including 10 ANDAs filed
76
Filings in the US pending for approval
20.4%
Women in leadership
96%
Employees trained for skill upgradation
0.14 to 0.07
*LTIFR reduced from
126
Differently abled employees
700,000+
Lives impacted through CSR
783
Million KL of water saved through agri-water saving techniques
66,723
MTCO2e of direct emissions reduction
11%
Reduction in water intensity per rupee of turnover with respect to FY2024
60%
Carbon neutrality achieved
75,761
KL of harvested rainwater used
54%
Water reused/recycled
Our Plants
What We Present at CPHI Japan 2026
APIs for Japan
A strong portfolio across major therapeutic areas:
- Cardiovascular, CNS, GI, Anti‑infectives
Oncology, Dermatology, Metabolic
disorders Including:
- Japan DMF‑filed APIs
- Complex APIs and value‑added technologies
- Pipeline APIs aligned to future market needs
Finished Dosage Forms (FDFs)
We showcase our FDF strength across:
- Oral solids, injectables, and complex generics
- R&D‑driven formulation expertise
- Supply, in‑licensing, and out‑licensing opportunities
Peptides
We highlight our peptide API capabilities, including:
- cGMP manufacturing operated with robust quality systems
- Flexible and scalable production (from grams to multi‑kg)
- Strong regulatory track record
- Collaboration options for peptide development through Aurigene and Dr. Reddy’s
- Support for both commercial supply and clinical requirements
CDMO & Custom Services (Aurigene + Dr. Reddy’s)
End‑to‑end development and manufacturing services:
- API development and scale‑up
- Peptide synthesis and manufacturing
- Small molecule CDMO
- Custom synthesis and process optimization
- Clinical to commercial supply
A trusted partner for companies seeking quality, reliability, and compliance.
Biosimilars
We present our global biosimilar portfolio with opportunities for Japan:
- Commercial and late‑stage biosimilars
- Flexible partnership and licensing models
- High‑quality and affordable biologics backed by strong clinical data
B2B Collaborations
We engage with partners across Japan for:
- Co‑development
- Licensing (in‑licensing and out‑licensing)
- Strategic sourcing and long‑term supply agreements
- Technology and R&D collaborations
Our goal is to build sustainable, trust‑based partnerships in the Japanese market.
Our Commitment to Japan
Across all business units — APIs, FDFs, Peptides, CDMO, and Biosimilars — our focus remains on:
- Quality and regulatory excellence
- Reliable and consistent supply
- Sustainable and compliant manufacturing
- Supporting Japan with future‑ready pharmaceutical solutions